Aziflu is developing new antiviral drugs against influenza (flu). Their focus is on treatments that work better than current agents, are less susceptible to resistance and can remain effective later in the infection.

Their compounds are designed to overcome current limitations in antiviral therapy, including resistance and reduced efficacy against emerging variants. By leveraging a unique approach based on covalent inhibition of viral neuraminidases, Aziflu aims to deliver more potent and durable antiviral solutions.